Compare RUM & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUM | CGEM |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | 2021 | 2020 |
| Metric | RUM | CGEM |
|---|---|---|
| Price | $9.50 | $22.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $30.13 |
| AVG Volume (30 Days) | ★ 4.0M | 673.3K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.72 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $100,622,320.00 | N/A |
| Revenue This Year | $209.98 | N/A |
| Revenue Next Year | $40.99 | $5.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.38 | N/A |
| 52 Week Low | $4.62 | $5.68 |
| 52 Week High | $10.60 | $23.19 |
| Indicator | RUM | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 70.60 | 69.69 |
| Support Level | $5.37 | $16.40 |
| Resistance Level | $10.54 | N/A |
| Average True Range (ATR) | 0.75 | 1.19 |
| MACD | 0.24 | 0.25 |
| Stochastic Oscillator | 76.92 | 89.31 |
RUM Group Inc focused is to maximize the power of human imagination through an independent technology ecosystem built on privacy, resilience, and an open alternative to Big Tech. Rumble gives human creativity a voice, a video and media platform built for creators and audiences who value free expression. Quake AI is a cloud and AI-infrastructure business, delivering the compute, data-center capacity, and blockchain infrastructure for the agentic era.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.